/
GHRS
$28.49+$0.27 (+0.96%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$1.9B
69M shares
52-week range
$11.32 – $28.96
97% from low
Exchange
NASDAQ
CS
Borrow rate
0.59%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$6.76
GH Research PLC Ordinary Shares
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
www.ghres.com- Employees
- 73
- IPO / List date
- Jun 25, 2021
Held by traders on TradeandTell
No one on the platform currently holds GHRS.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in GHRS as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded GHRS yet.
